del(4)(p16p16) FGFR3::TACC3
Oncogenic mechanisms
Constitutive activation of FGFR3 tyrosine kinase activity
Targeted therapy
Erdafitinib
Tumor type
Glioblastoma multiforme
Bladder Urothelial Carcinoma
Lung adenocarcinoma
Head and Neck squamous cell carcinoma
Brain Lower Grade Glioma
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 27245147 | 2016 | FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). | 137 |
| 38197196 | 2023 | TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness. | 122 |
| 35436952 | 2022 | Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. | 113 |
| 35955806 | 2022 | FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. | 99 |
| 38067258 | 2023 | Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives. | 87 |
| 32085805 | 2020 | FGFR- gene family alterations in low-grade neuroepithelial tumors. | 78 |
| 36142417 | 2022 | FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer. | 75 |
| 37980380 | 2023 | Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. | 73 |
| 36827114 | 2023 | Stellettin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. | 72 |
| 36194351 | 2023 | Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. | 70 |
| 33853673 | 2021 | Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs. | 66 |
| 34160364 | 2021 | Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. | 64 |
| 29323298 | 2018 | A metabolic function of FGFR3-TACC3 gene fusions in cancer. | 61 |
| 29991799 | 2018 | FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. | 59 |
| 32414213 | 2020 | Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma. | 58 |
| 36002559 | 2022 | In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. | 56 |
| 35151844 | 2022 | HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion. | 54 |
| 29262532 | 2017 | Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis. | 54 |
| 31987043 | 2020 | FGFR3 signaling and function in triple negative breast cancer. | 54 |
| 37720238 | 2023 | Bladder cancer course, four genetic high-risk variants, and histopathological findings. | 54 |
| 38813112 | 2024 | TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma. | 52 |
| 27930669 | 2016 | Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. | 50 |
| 36776367 | 2022 | Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis. | 48 |
| 27345413 | 2017 | FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. | 47 |
| 29358619 | 2018 | Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. | 46 |
| 37210288 | 2023 | Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights. | 44 |
| 33168106 | 2020 | Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. | 44 |
| 34247193 | 2021 | Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. | 44 |
| 27409839 | 2016 | FGFR3-TACC3 fusion in solid tumors: mini review. | 42 |
| 38730596 | 2024 | Diffuse Gliomas with FGFR3::TACC3 Fusion: Morphological and Molecular Features and Classification Challenges. | 42 |
| 36216793 | 2022 | Human papillomavirus integration perspective in small cell cervical carcinoma. | 41 |
| 23298836 | 2013 | The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. | 41 |
| 34522456 | 2021 | Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. | 41 |
| 38074682 | 2023 | Polymorphous low-grade neuroepithelial tumor of the young with FGFR3-TACC3 fusion mimicking high-grade glioma: case report and series of high-grade correlates. | 40 |
| 24476821 | 2014 | Comprehensive molecular characterization of urothelial bladder carcinoma. | 39 |
| 32413119 | 2020 | Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. | 39 |
| 33898054 | 2021 | FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. | 39 |
| 31290679 | 2019 | Comparative proteogenomic characterization of glioblastoma. | 38 |
| 25609060 | 2015 | Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. | 38 |
| 38312227 | 2024 | Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. | 37 |
| 35222252 | 2022 | Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review. | 36 |
| 36647073 | 2023 | Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion. | 36 |
| 30344944 | 2018 | Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. | 36 |
| 38255255 | 2024 | Clinicopathological and Molecular Characteristics of IDH-Wildtype Glioblastoma with FGFR3::TACC3 Fusion. | 36 |
| 39717713 | 2024 | CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo. | 36 |
| 28379477 | 2017 | Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. | 36 |
| 39848978 | 2025 | Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3. | 36 |
| 36780330 | 2023 | Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability. | 33 |
| 28855393 | 2017 | FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle. | 33 |
| 35344029 | 2022 | Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. | 33 |
| 39211518 | 2024 | Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma. | 33 |
| 33604498 | 2018 | Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. | 32 |
| 34274537 | 2021 | Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma. | 31 |
| 30064409 | 2018 | Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. | 31 |
| 34036234 | 2021 | Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization. | 31 |
| 25535896 | 2014 | Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. | 30 |
| 38496910 | 2024 | RT-PCR assay to detect FGFR3::TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples. | 29 |
| 22837387 | 2012 | Transforming fusions of FGFR and TACC genes in human glioblastoma. | 28 |
| 33241214 | 2020 | RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. | 28 |
| 28976058 | 2018 | Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. | 24 |
| 35566609 | 2022 | FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). | 23 |
| 36134017 | 2022 | Extra-CNS and dural metastases in FGFR3::TACC3 fusion+ adult glioblastoma, IDH-wildtype. | 22 |
| 32949176 | 2021 | Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. | 21 |
| 23298839 | 2013 | Multiple functions of a glioblastoma fusion oncogene. | 21 |
| 33604497 | 2018 | Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. | 16 |
| 28838400 | 2017 | Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. | 15 |
| 26425723 | 2015 | FGFR3-TACC3: A novel gene fusion in cervical cancer. | 15 |
| 37214414 | 2023 | Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report. | 10 |
| 31036092 | 2019 | Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases. | 9 |
| 35567606 | 2022 | DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. | 9 |
| 35085722 | 2022 | Development of a degrader against oncogenic fusion protein FGFR3-TACC3. | 0 |
| 32854916 | 2020 | Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib. | 0 |
| 38701794 | 2024 | Retraction Notice to: Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma. | 0 |
| 36455273 | 2022 | Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas. | 0 |
| 26869289 | 2016 | Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. | 0 |
| 29330265 | 2018 | FGFR3-TACC3 Activates Mitochondrial Respiration via PIN4 Phosphorylation. | 0 |
| 34766555 | 2021 | Targeting gene fusions in glioma. | 0 |
| 39306889 | 2024 | Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma. | 0 |
| 32199932 | 2021 | Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration. | 0 |
| 39387893 | 2024 | FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity. | 0 |
| 25294908 | 2014 | Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. | 0 |
| 31810398 | 2020 | Erdafitinib for the treatment of metastatic bladder cancer. | 0 |
| 36530080 | 2023 | Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. | 0 |
| 33769273 | 2021 | Can adult IDH-wildtype glioblastomas with FGFR3:TACC3 fusions be reliably predicted by histological features? | 0 |
| 27771611 | 2017 | Identification of a FGFR3-TACC3 fusion in esophageal cancer. | 0 |
| 31078809 | 2019 | Recurrent Papillary Glioneuronal Tumor. | 0 |
| 38084010 | 2024 | Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement : Clinicopathologic and Next Generation Sequencing Study of 7 Cases. | 0 |
| 30379640 | 2019 | The role of fibroblast growth factors and their receptors in gliomas: the mutations involved. | 0 |
| 38971117 | 2024 | Novel gene fusions in human oropharyngeal carcinoma. | 0 |
| 32217742 | 2020 | A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate. | 0 |
| 35347013 | 2022 | Oncogenic Fusions in Gliomas: An Institutional Experience. | 0 |
| 35066105 | 2022 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. | 0 |
| 31735287 | 2019 | Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. | 0 |
| 24452392 | 2014 | A novel somatic FGFR3 mutation in primary lung cancer. | 0 |
| 37584165 | 2023 | Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. | 0 |
| 39126751 | 2024 | HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report. | 0 |
| 30213523 | 2019 | Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. | 0 |
| 21380501 | 2011 | Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". | 0 |
| 34663543 | 2022 | Differences in genomic profile of high-grade urothelial carcinoma according to tumor location. | 0 |
| 31959344 | 2020 | Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. | 0 |
Bibliography
| Pubmed ID | Publication Year | Title | Authors |
|---|---|---|---|
| 30344944 | 2018 | Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. | Nelson KN, et al |
| 25294908 | 2014 | Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. | Capelletti M, et al |
| 25500544 | 2015 | The landscape and therapeutic relevance of cancer-associated transcript fusions. | Yoshihara K, et al |
